{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants will receive Prochymal\u00ae consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.",
            "Participants will receive Prochymal\u00ae consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses."
      ],
      "ArmGroupInterventionName": [
            "Drug: Prochymal\u00ae - 2 Million cells/kg",
            "Drug: Methylprednisolone",
            "Drug: Prednisone",
            "Drug: Cyclosporine",
            "Drug: Tacrolimus",
            "Drug: Mycophenolate Mofetil",
            "Drug: Prochymal\u00ae- 8 Million cells/kg",
            "Drug: Methylprednisolone",
            "Drug: Prednisone",
            "Drug: Cyclosporine",
            "Drug: Tacrolimus",
            "Drug: Mycophenolate Mofetil"
      ],
      "ArmGroupLabel": [
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00136903"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal\u00ae) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant."
      ],
      "BriefTitle": [
            "Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "July 14, 2008"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Graft Vs Host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "All",
            "BC15",
            "BC20",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "All Conditions",
            "Blood and Lymph Conditions",
            "Immune System Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft vs Host Disease",
            "Graft vs Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M10097",
            "M10372",
            "M8341",
            "M9352",
            "T3543",
            "T2832",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Leukemia",
            "Lymphoma",
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Lymphosarcoma",
            "Homologous Wasting Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "low",
            "high",
            "low",
            "low",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Protocol 260 - Participants will be randomized with equal probability to the treatment arms (2 million cells/kilogram (kg) of Prochymal\u00ae or 8 million cells/kg of Prochymal\u00ae) using a stratified block design. The stratification factor is acute GVHD grade. For the purpose of stratification, the GVHD grades are II and III-IV. Treatment with investigational agent will be administered on study Days 1 and 4. Participants will be followed for safety and efficacy until Day 28 after initiation of treatment with the investigational agent, or until withdrawal or death, whichever occurs first.\n\nProtocol 261- This study is designed as a long-term safety follow-up of participants who take part in the preceding clinical study of Prochymal\u00ae (Protocol 260) for the treatment of acute GVHD. Participants will be enrolled in Study 261 upon completion of the preceding Study 260."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Protocol 260 Inclusion Criteria:\n\nParticipant must be 18 to 70 years of age inclusive.\nIf female and of child-bearing age, participant must be non-pregnant, not breast feeding, and use adequate contraception. Males must use adequate contraception.\nParticipant must have newly diagnosed, Grade II-IV acute GVHD requiring therapy. Biopsy for confirmation of GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.\nParticipant must have received either full or reduced intensity myeloablative regimens followed by an allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cell, or cord blood, including donor lymphocyte infusion (DLI).\n\nParticipant must have minimal renal and hepatic function as defined by:\n\n* Calculated creatinine clearance (CLcr) of > 30 mL/min using the Cockroft-Gault equation.\n\nParticipant must be available for all specified assessments at the study site through study Day 28.\nParticipant must provide written informed consent and authorization for use and disclosure of protected health information (PHI).\n\nProtocol 260 Exclusion Criteria:\n\nParticipant has received previous treatment for Grade II-IV acute GVHD (except as noted in Criterion 2).\nParticipant has been treated for GVHD with methylprednisolone, > 2mg/kg/day, for more than 72 hours prior to receiving Prochymal\u00ae.\nParticipant has uncontrolled alcohol or substance abuse within 6 months of randomization.\nParticipant has received an investigational agent (not approved by food and drug administration (FDA) for marketed use in any indication) within 30 days of randomization. Participant may not receive an investigational agent during the 28-day study period.\nParticipant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.).\nParticipant has unstable arrhythmia.\nParticipant is unwilling to sign consent form for the long-term follow-up study, Protocol 261.\nParticipant has a known allergy to bovine or porcine products.\nParticipant had received transplant for a solid tumor disease."
      ],
      "EnrollmentCount": [
            "32"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000005938",
            "D000006728",
            "D000006730",
            "D000045505",
            "D000018931",
            "D000000970",
            "D000007166",
            "D000007155",
            "D000065095",
            "D000004791",
            "D000045504",
            "D000000935",
            "D000000890",
            "D000003879",
            "D000018501",
            "D000000903",
            "D000000904",
            "D000000995",
            "D000000900",
            "D000000932",
            "D000001337",
            "D000018373",
            "D000005765",
            "D000018696",
            "D000020011",
            "D000000998"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormones, Hormone Substitutes, and Hormone Antagonists",
            "Physiological Effects of Drugs",
            "Antineoplastic Agents, Hormonal",
            "Antineoplastic Agents",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Calcineurin Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action",
            "Antifungal Agents",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Antibiotics, Antineoplastic",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Anti-Bacterial Agents",
            "Antiemetics",
            "Autonomic Agents",
            "Peripheral Nervous System Agents",
            "Gastrointestinal Agents",
            "Neuroprotective Agents",
            "Protective Agents",
            "Antiviral Agents"
      ],
      "InterventionArmGroupLabel": [
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg",
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg",
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg",
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg",
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg",
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae - 8 Million cells/kg"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All",
            "ANeo",
            "Infl",
            "AnEm",
            "NeuroAg",
            "Gast"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals",
            "Antineoplastic Agents",
            "Anti-Inflammatory Agents",
            "Antiemetics",
            "Neuroprotective Agents",
            "Gastrointestinal Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "Impact",
            "Impact",
            "Bolus",
            "Neck",
            "Cardiac",
            "Until",
            "1440"
      ],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882",
            "M11280",
            "M13272",
            "M1833",
            "M10901",
            "M10902",
            "M229437",
            "M211896",
            "M248768",
            "M18102",
            "M13273",
            "M186752",
            "M3369",
            "M8199",
            "M8941",
            "M8940",
            "M20119",
            "M9364",
            "M9353",
            "M29605",
            "M3406",
            "M5404",
            "M10948",
            "M3366",
            "M6226",
            "M19757",
            "M3374",
            "M3376",
            "M3463",
            "M3403",
            "M8033",
            "M19926",
            "M21022",
            "M3466"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins",
            "Mycophenolic Acid",
            "Prednisolone",
            "Methylprednisolone Acetate",
            "Methylprednisolone",
            "Methylprednisolone Hemisuccinate",
            "Prednisolone acetate",
            "Prednisolone hemisuccinate",
            "Prednisolone phosphate",
            "Tacrolimus",
            "Prednisone",
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormone Antagonists",
            "Antineoplastic Agents, Hormonal",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Calcineurin Inhibitors",
            "Antifungal Agents",
            "Clotrimazole",
            "Miconazole",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Anti-Bacterial Agents",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Antiemetics",
            "Gastrointestinal Agents",
            "Neuroprotective Agents",
            "Protective Agents",
            "Antiviral Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "2 million hMSCs/kg actual body weight, IV on study Days 1 and 4",
            "8 million hMSCs/kg actual body weight IV on study Days 1 and 4",
            "Methylprednisolone 2 mg/kg administered intravenously.",
            "Prednisone 2.5 mg/kg administered orally.",
            "Administered as prescribed by the caregiver.",
            "Administered as prescribed by the caregiver.",
            "Administered as prescribed by the caregiver."
      ],
      "InterventionMeshId": [
            "D000016572",
            "D000009173",
            "C000711674",
            "D000011241",
            "D000008775",
            "D000016559",
            "D000003524"
      ],
      "InterventionMeshTerm": [
            "Cyclosporine",
            "Mycophenolic Acid",
            "Remestemcel-l",
            "Prednisone",
            "Methylprednisolone",
            "Tacrolimus",
            "Cyclosporins"
      ],
      "InterventionName": [
            "Prochymal\u00ae - 2 Million cells/kg",
            "Prochymal\u00ae- 8 Million cells/kg",
            "Methylprednisolone",
            "Prednisone",
            "Cyclosporine",
            "Tacrolimus",
            "Mycophenolate Mofetil"
      ],
      "InterventionOtherName": [
            "Remestemcel-L",
            "ex-vivo cultured adult human mesenchymal stem cells",
            "hMSCs",
            "Remestemcel-L",
            "ex-vivo cultured adult human mesenchymal stem cells",
            "hMSCs"
      ],
      "InterventionType": [
            "Drug",
            "Drug",
            "Drug",
            "Drug",
            "Drug",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Graft vs Host Disease",
            "(GVHD)",
            "Graft Versus Host Disease",
            "Bone marrow transplant",
            "Stem cells",
            "Mesenchymal stem cells (MSCs)",
            "Adult stem cells",
            "Leukemia",
            "Lymphoma"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 31, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 14, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Indianapolis",
            "Kansas City",
            "Hackensack",
            "Buffalo",
            "New York",
            "Rochester",
            "Valhalla",
            "Houston",
            "Milwaukee"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "St. Francis Hospital",
            "Kansas City Cancer Centers - BMT",
            "The Cancer Center at Hackensack University",
            "Roswell Park Cancer Institute",
            "Mt. Sinai Hospital",
            "University of Rochester",
            "New York Medical College",
            "MD Anderson Cancer Center",
            "Medical College of Wisconsin, FEC"
      ],
      "LocationState": [
            "Indiana",
            "Missouri",
            "New Jersey",
            "New York",
            "New York",
            "New York",
            "New York",
            "Texas",
            "Wisconsin"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "46237",
            "64111",
            "07601",
            "14263",
            "10029",
            "14642",
            "10595",
            "77030",
            "53226"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [
            "NCT00476762"
      ],
      "OfficialTitle": [
            "A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "260-261"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Christopher James, PA"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "July 28, 2006"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)",
            "Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal\u00ae in the preceding study (Protocol No. 260)."
      ],
      "PrimaryOutcomeTimeFrame": [
            "28 Days",
            "2 Years"
      ],
      "ReferenceCitation": [
            "Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8.",
            "Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. Review.",
            "Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98.",
            "Le Blanc K, Rasmusson I, Sundberg B, G\u00f6therstr\u00f6m C, Hassan M, Uzunel M, Ringd\u00e9n O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.",
            "Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. Review.",
            "Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Jul;15(7):804-11. doi: 10.1016/j.bbmt.2008.03.012."
      ],
      "ReferencePMID": [
            "11823036",
            "10989188",
            "15846293",
            "15121408",
            "16040382",
            "19539211"
      ],
      "ReferenceType": [
            "background",
            "background",
            "background",
            "background",
            "background",
            "result"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,",
            "Protocol 260 - Time to best response of GVHD",
            "Protocol 260 - Time to improvement of GVHD in one or more organs",
            "Protocol 261 - Survival through study day 90"
      ],
      "SecondaryOutcomeTimeFrame": [
            "28 Days",
            "28 Days",
            "28 Days",
            "90 Days"
      ],
      "SeeAlsoLinkLabel": [
            "Click here for more information on Prochymal\u00ae for treatment of GVHD"
      ],
      "SeeAlsoLinkURL": [
            "http://www.osiristx.com"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "April 27, 2005"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "August 29, 2005"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "August 25, 2005"
      ],
      "StudyFirstSubmitQCDate": [
            "August 25, 2005"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}